Amarin Corp Plc (AMRN)

[raistthemage]

If the FDA denies Anchor in December the company has to focus on achieving profitability with the current indication... not spending its limited resources dealing with more FDA bull****

This means

1) Cutting unnecessary cost - which will include running the Reduce It study. The company should discontinue immediately the minute it becomes certain there is no hope of the FDA overruling its advisory panel.

2) Marketing to all expanded indications anyway.


I think they probably should sue the FDA even if they can't win for reasons of publicity... cockroaches and corrupt FDA employees in bed with big pharma will both run for cover from the light. Hell they might win if it surfaces that someone really was paid off (I'm almost certain payoffs were involved, what I don't know is how well the tracks were covered if they weren't covered too well it might come out in a court case). In any case Vascepa will get favorable publicity.

They don't need to worry about generic competition till their patents expire either, and the FDA and the patent office are two entirely different groups.